DART trial: Immune checkpoint combo shows promise for high-grade neuroendocrine carcinoma

3 Views
administrator
administrator
07/09/23

Dual immune checkpoint blockade with ipilimumab and nivolumab was well tolerated in patients with neuroendocrine cancer and showed particular efficacy in those with high-grade tumors, according to findings from a prospective, open-label, phase 2 basket trial. Dr. Sandip Pravin Patel discusses the results. Learn more at www.mdedge.com.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next